CG Oncology Inc.(CGON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGON CG Oncology Inc.

Trading 11-04 13:19:54 EST

66.08

+2.02

+3.15%

High66.15	Low63.16	Vol475.24K
Open66.10	D1 Closing64.06	Amplitude4.67%
Mkt Cap5.86B	Tradable Cap5.13B	Total Shares88.64M
T/O30.75M	T/O Rate0.61%	Tradable Shares77.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGON","market":"US","secType":"STK","nameCN":"CG Oncology Inc.","latestPrice":66.075,"timestamp":1793816393933,"preClose":64.06,"halted":0,"volume":475243,"delay":0,"changeRate":0.03145488604433345,"floatShares":77710152,"shares":88640375,"eps":-2.72351,"marketStatus":"Trading","change":2.015,"latestTime":"11-04 13:19:54 EST","open":66.1,"high":66.15,"low":63.16,"amount":30754663.543622002,"amplitude":0.046675,"askPrice":66.23,"askSize":31,"bidPrice":65.94,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-2.72351,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793826000000},"marketStatusCode":2,"adr":0,"listingDate":1706158800000,"exchange":"NASDAQ","adjPreClose":64.06,"preHourTrading":{"tag":"盘前","latestPrice":65.1,"preClose":64.06,"latestTime":"09:27 EST","volume":723,"amount":46613.41505999999,"timestamp":1793802470046,"change":1.04,"changeRate":0.016235,"amplitude":0.014674},"postHourTrading":{"tag":"盘后","latestPrice":64.06,"preClose":64.06,"latestTime":"19:41 EST","volume":12388,"amount":793670.22,"timestamp":1793752890295,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.875628,"optionData":{"bulkOrders":[{"symbol":"CGON","call":false,"expireDate":1795150800000,"strike":"50.0","timestamp":1793805001907,"price":3.6,"volume":2750,"amount":990000,"type":"-"},{"symbol":"CGON","call":true,"expireDate":1799989200000,"strike":"75.0","timestamp":1793809189946,"price":8.8,"volume":2000,"amount":1760000,"type":"+"}]},"impliedVol":1.3338,"impliedVolPercentile":0.9602},"requestUrl":"/m/hq/s/CGON/tweets","defaultTab":"tweets","newsList":[{"id":"2680727972","title":"Genmab Share Price Surge Puts These Oncology Stocks In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2680727972","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680727972?lang=en_us&edition=fundamental","pubTime":"2026-11-03 21:21","pubTimestamp":1793712114,"startTime":"0","endTime":"0","summary":"Oncology biotech is having a moment again, and Genmab is at the center of it after three Phase 3 wins and a share price that has doubled in just three months. When one developer suddenly has multiple cancer drug contenders, attention often spills over into other treatment players that might benefit from the same wave of interest or face tougher competition. This article unpacks what that shift could mean by walking through three oncology stocks that are directly exposed to the latest Genmab...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/genmab-share-price-surge-puts-these-oncology-stocks-in-focus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/genmab-share-price-surge-puts-these-oncology-stocks-in-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2324357040.USD","BK4526","ONC","BK4139","ZYME","BK4588","SBIO","CGON","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677950048","title":"CG Oncology (CGON) CCO Hire Puts Its Launch Valuation Narrative To The Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2677950048","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677950048?lang=en_us&edition=fundamental","pubTime":"2026-10-22 16:36","pubTimestamp":1792658166,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) has put commercial execution in sharper focus after appointing industry veteran Isabel Kalofonos as Chief Commercial Officer. The move is tied directly to preparations for a possible cretostimogene grenadenorepvec launch.\nFor context, CG Oncology shares trade at US$62.24, with the stock delivering a 48.94% year to date share price return and a 48.51% total shareholder return over the past year. This comes even after a 20.46% decline in the 30 day share price, which suggests...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-cco-hire-puts-its-launch-valuation-narrativ","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-cco-hire-puts-its-launch-valuation-narrativ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4009","BK4139","LU2357125470.USD","LU0823414551.USD","LU0823414478.USD","LU2294711713.HKD","CGON","CCO","LU2324357040.USD","SBIO","LU2506951792.HKD","LU2249611893.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676636504","title":"CG Oncology Director Leonard E. Post Reports Sale of Common Shares Worth $62,065","url":"https://stock-news.laohu8.com/highlight/detail?id=2676636504","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676636504?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:31","pubTimestamp":1792441879,"startTime":"0","endTime":"0","summary":"CG Oncology Director Leonard E. Post Reports Sale of Common Shares Worth $62,065CG Oncology director Leonard E. Post sold 1,000 common shares on Oct. 15, 2026.The sales comprised 500 shares at $61.65 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL8CNWVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CG Oncology Director Leonard E. Post Reports Sale of Common Shares Worth $62,065","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","SBIO","BK4139","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676063576","title":"CG Oncology Files Initial Beneficial Ownership Statement for Chief Commercial Officer Isabel Kalofonos","url":"https://stock-news.laohu8.com/highlight/detail?id=2676063576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676063576?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:16","pubTimestamp":1792440969,"startTime":"0","endTime":"0","summary":"CG Oncology Files Initial Beneficial Ownership Statement for Chief Commercial Officer Isabel KalofonosCG Oncology Chief Commercial Officer Isabel Kalofonos filed an initial statement of beneficial own","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDLc2yDh0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4139","SBIO","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675235114","title":"CG Oncology Names Isabel Kalofonos Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675235114","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675235114?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:08","pubTimestamp":1791893295,"startTime":"0","endTime":"0","summary":"CG Oncology names Isabel Kalofonos chief commercial officerCG Oncology named Isabel Kalofonos as chief commercial officer as it prepares for a potential launch of cretostimogene grenadenorepvec.Kalofo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL1Tw2QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","PPH","LU2324357040.USD","LU0211328371.USD","LU2237443465.HKD","IYH","IBBQ","LU2468319806.SGD","IE00B894F039.SGD","GNMX","PJP","RXL","BCDF","IE00BN8TJ469.HKD","TRUH","LU2089284900.SGD","BBH","PBE","VHT","IE0004445239.USD","GLAM","IXJ","LU1551013425.SGD","LU0820561909.HKD","LU0158827948.USD","LU0432979614.USD","SBIO","MEDX","TBXU","VRTX","XLV","FHLC","CGON","AGNG","LU1720051017.SGD","LU2089984988.USD","IE000BZT7R73.USD","IE00BSNM7G36.USD","JDOC","LU0965509010.AUD","FTXH","SG9999001440.SGD","IE00BFTCPJ56.SGD","NDAQ","BIB","ABBV","LU1291159041.SGD","IE00BKPKM429.USD","LU2210150020.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675351843","title":"CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675351843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675351843?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:00","pubTimestamp":1791892809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nTUA6FTCDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","BK4139","LU2324357040.USD","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668992677","title":"CG Oncology Director Leonard E. Post Disposes of 1,000 Common Shares Worth $72,980","url":"https://stock-news.laohu8.com/highlight/detail?id=2668992677","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668992677?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:31","pubTimestamp":1789677113,"startTime":"0","endTime":"0","summary":"CG Oncology director Leonard E. Post disposes of 1,000 common shares worth $72,980CG Oncology director Leonard E. Post sold 1,000 shares on Sep. 15, 2026 at USD 72.98.He also exercised director stock ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL2LTwlF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CG Oncology Director Leonard E. Post Disposes of 1,000 Common Shares Worth $72,980","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON","LU2324357040.USD","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733819","title":"CG Oncology CEO Joins Cantor Fitzgerald Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733819","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664733819?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:05","pubTimestamp":1788350700,"startTime":"0","endTime":"0","summary":"CG Oncology CEO joins Cantor Fitzgerald Global Healthcare Conference fireside chatCG Oncology will join investor conference fireside chats in New York City on Sept. 9, 2026, Sept. 14, 2026.Chairman, P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL79SQcv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","NDAQ","LU0158827781.USD","SG9999014013.SGD","IE00BGHQF748.EUR","CGON","LU0557290698.USD","LU1162221912.USD","LU2023251221.USD","BK4112","BK4504","LU1720051017.SGD","LU1989772923.USD","LU1074936037.SGD","IAI","BK4534","IE00BQXX3D17.EUR","LU2487616109.SGD","SBIO","BK4127","LU2210150020.SGD","LU0528227936.USD","BK4585","IE00B64PRP62.GBP","BK4516","LU1732799900.SGD","BCDF","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","BK4588","LU0234570918.USD","KBWB","LU0106261372.USD","LU1988902786.USD","LU1989772840.SGD","SG9999014039.USD","SG9999014005.SGD","IE00B3S45H60.SGD","BK4581","LU2089284900.SGD","LU0971096721.USD","IE00BN0W2V16.EUR","LU0158827948.USD","LU2089283258.USD","LU1244550221.USD","LU0795875169.SGD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU0320765646.SGD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811865","title":"CG Oncology to Present at Upcoming Investor Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811865","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811865?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350400,"startTime":"0","endTime":"0","summary":"DALLAS, Sept.  02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presenta","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355052/0/en/cg-oncology-to-present-at-upcoming-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0971096721.USD","LU1988902786.USD","BK4581","LU2357305700.SGD","SBIO","LU1244550494.USD","LU2133065610.SGD","LU0314104364.USD","KBWB","CGON","BK4504","LU1732799900.SGD","LU1732800096.USD","LU1791710582.SGD","LU0557290698.USD","LU0882574139.USD","LU0106831901.USD","LU0158827948.USD","LU2271345857.HKD","LU1363072403.SGD","LU0106261372.USD","LU2324357040.USD","BK4127","LU0528227936.USD","LU0795875086.SGD","LU0320765646.SGD","LU0795875169.SGD","LU0225283273.USD","LU1668664300.SGD","LU1244550221.USD","LU2089284900.SGD","LU2111349929.HKD","LU0006306889.USD","LU1074936037.SGD","BK4534","IE00B775SV38.USD","BK4516","BK4585","IAI","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1162221912.USD","LU1720051017.SGD","LU0912757837.SGD","LU2028103732.USD","IE00B3S45H60.SGD","LU0390134368.USD","LU2089283258.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660788289","title":"UBS Keeps Their Buy Rating on CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660788289","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660788289?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:35","pubTimestamp":1787225729,"startTime":"0","endTime":"0","summary":"In a report released today, David Dai from UBS maintained a Buy rating on CG Oncology, Inc., with a price target of $90.00. Dai covers the Healthca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-keeps-their-buy-rating-on-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-keeps-their-buy-rating-on-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGON","CG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492308","title":"CG Oncology Director Leonard Post Disposes of USD 74,540 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492308","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492308?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:31","pubTimestamp":1787085070,"startTime":"0","endTime":"0","summary":"CG Oncology director Leonard Post disposes of USD 74,540 in common sharesCG Oncology director Leonard E. Post sold 1,000 common shares at USD 74.54 on Aug. 14, 2026.The sale followed the exercise of 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL77wBqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CG Oncology Director Leonard Post Disposes of USD 74,540 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187819","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: CG Oncology, Inc. (CGON) and Zimmer Biomet Holdings (ZBH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659187819?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:30","pubTimestamp":1786588220,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on CG Oncology, Inc. (CGON) and Zimmer Biomet Holdings (ZBH). CG Onc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cg-oncology-inc-cgon-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cg-oncology-inc-cgon-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPZ","LU0648001328.SGD","IE00B19Z3B42.SGD","LU0029864427.USD","LU0310799852.SGD","LU0130102774.USD","LU0211327993.USD","BK4082","BK4135","BK4585","LU0708994859.HKD","IE0002270589.USD","LU0211328371.USD","IE00B7SZLL34.SGD","LU0128525929.USD","LU1267930813.SGD","IE00BGHQF748.EUR","LU0980610538.SGD","BK4588","BK4137","ZBH","LU0310800379.SGD","LU0477156953.USD","CG","LU0792757196.USD","BK4566","IE00B64PRP62.GBP","LU0128526141.USD","LU1201861249.SGD","XBI","IE00B19Z3581.USD","BK4139","BK4581","LU0889566641.SGD","XLV","LU1267930573.SGD","HCSG","SBIO","CGON","BK4504","LU1267930490.SGD","LU0029874061.USD","LU0006061336.USD","LU0130517989.USD","IE00B3QW5Z07.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649914","title":"CG Oncology Price Target Raised to $85.00/Share from $82.00 by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649914","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649914?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:23","pubTimestamp":1786108980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657102816","title":"RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657102816","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657102816?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:15","pubTimestamp":1786101301,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) has an average rating of buy and mean price target of $91.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGON","CG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666539","title":"Zentalis Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666539","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666539?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:36","pubTimestamp":1786052164,"startTime":"0","endTime":"0","summary":"Zentalis Q2 net loss widens on higher R&D costsOverviewOncology drug developer's Q2 net loss widened as R&D expenses rose on trial milestonesCompany completed enrollment in DENALI Part 2a and 2b, adva","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139","ALXO","SBIO","REPL","ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657066508","title":"Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657066508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657066508?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:20","pubTimestamp":1786051212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InflaRx (IFRX), CG Oncology, Inc. (CGON) and Edgewis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inflarx-ifrx-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inflarx-ifrx-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CG","CGON","BK4139","XLV","SBIO","LU0029874061.USD","BK4135","GPZ","IE00B3QW5Z07.USD","BK4581","XBI","IE00BGHQF748.EUR","HCSG","BK4585","BK4137","IE00B64PRP62.GBP","LU0128526141.USD","IFRX","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657689246","title":"TriSalus Life Sciences Q2 Revenue Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657689246","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657689246?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:32","pubTimestamp":1786048347,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences Q2 revenue beats estimatesOverviewOncology device maker's Q2 revenue rose yr/yr, beating analyst expectationsCompany maintained 2026 revenue guidance of $54 mln to $57 mlnOperat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI","BK4139","CHRS","CGON","DCTH","BK4535","BK4082","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650667","title":"Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650667","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650667?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:16","pubTimestamp":1786047402,"startTime":"0","endTime":"0","summary":"Biopharma firm IN8bio's Q2 net loss narrows as expenses declineOverviewUS biopharma firm's Q2 net loss narrowed yr/yr, with flat R&D and lower G&A expensesCompany reported updated clinical data showin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CGON","INAB","BK4139","SBIO","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763093","title":"CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763093","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763093?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:21","pubTimestamp":1786026089,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. reports results for the quarter ended June 30 - Earnings SummaryCG Oncology, Inc.CGON.OQreported a quarterly adjusted loss of 90 cents per share for the quarter ended June 30, lower ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44329Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SBIO","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657263440","title":"CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657263440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657263440?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:04","pubTimestamp":1786021455,"startTime":"0","endTime":"0","summary":"CG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programsCG Oncology highlighted Phase 3 BOND-003 Cohort C in high-risk BCG-unresponsive CIS, reporting 76% compl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8wxmhj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://cgoncology.com;ir.cgoncology.com","stockEarnings":[{"period":"1week","weight":0.0178},{"period":"1month","weight":-0.0493},{"period":"3month","weight":-0.1154},{"period":"6month","weight":-0.074},{"period":"1year","weight":0.5289},{"period":"ytd","weight":0.5429}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CG Oncology, Inc. was originally incorporated in California on September 24, 2010, and later reincorporated in Delaware on November 30, 2017. The company is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for the treatment of bladder cancer. Its clinical programs target patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer who have limited treatment options.","exchange":"NASDAQ","name":"CG Oncology Inc.","nameEN":"CG Oncology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CG Oncology Inc.(CGON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CG Oncology Inc.(CGON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CG Oncology Inc.,CGON,CG Oncology Inc.股票,CG Oncology Inc.股票老虎,CG Oncology Inc.股票老虎国际,CG Oncology Inc.行情,CG Oncology Inc.股票行情,CG Oncology Inc.股价,CG Oncology Inc.股市,CG Oncology Inc.股票价格,CG Oncology Inc.股票交易,CG Oncology Inc.股票购买,CG Oncology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CG Oncology Inc.(CGON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CG Oncology Inc.(CGON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}